Business
Cancer centre shows Parsortix use in melanoma
Cancer centre shows Parsortix use in melanoma.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 5551S Angle PLC 07 November 2019 \n\n\n\n\nFor immediate release\n\n\n 7 November 2019\n\n\n\n \nANGLE plc (\"the Company\")\n \nLEADING CANCER CENTRE DEMONSTRATES USE OF PARSORTIX IN MELANOMA\n \nParsortix harvests cancer cells from blood for analysis where cell surface markers systems are limited\n \nCTCs predicted relapse earlier than standard of care imaging\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that leading European cancer centre, University Medical Centre Hamburg-Eppendorf (UKE), Germany has published results of work demonstrating that ANGLE's Parsortix® system can be used as a liquid biopsy to investigate prediction and monitoring of therapy responses for melanoma patients. \n \nMalignant melanoma is the deadliest form of skin cancer, with a global incidence of 290,000 per annum and 970,000 people living with the disease (source Globocan 2018). The disease is highly heterogeneous and the publication states that \"reliable biomarkers, which allow the prediction of therapeutic response and/or the development of therapeutic resistance as early as possible, are urgently needed\".\n \nThe results of the study by UKE have been published in the renowned peer-reviewed medical journal, Cancers. In the research, UKE used Parsortix over a five-year period, with follow-up in some cases for three years, the results showing that Parsortix can harvest circulating tumor cells (CTCs) from some melanoma patients, where other cell surface marker dependent systems are unable to do so. \n \nThis development holds the potential to shift current treatment options for melanoma. Analysis of CTCs harvested from melanoma patients opens up the potential for Parsortix's use as a companion diagnostic to select appropriate therapies and regularly monitor patients with melanoma, ensuring any potential relapse is flagged early and patients can receive the best treatment possible. The researchers demonstrated that the presence of CTCs in a patient's blood sample (where in a previous sample they had been absent) indicated relapse earlier than standard of care imaging techniques.\n \nANGLE's Founder and Chief Executive, Andrew Newland, commented:\n\"As the deadliest form of skin cancer, there is a clear need fo...